Nov 2023
View in browser
Снимок экрана 2022-03-23 в 22.31 1
social final

 November 2023

 

This month we are celebrating CIC's 10th anniversary and a decade of innovation.  The photographs above are from a celebration we recently hosted to thank all of the friends and colleagues that have supported us.  We have also created a short animation 'A Decade of Innovation' which you can view below.

 

It has been a busy quarter in the CIC portfolio.  We announced a new high profile investment in Prof. Allan Bradley's latest company, T-Therapeutics.  We also sold Allan's previous company, PetMedix, to Zoetis and sold Imagen to Thomson Reuters. 

 

It has been a busy few months on the policy front.  CIC welcomed the recent Mansion House compact, where leading pension funds committed 5% of their investments to the UK private growth sector.  CIC was also a leading signatory of the recent VC compact, announcing our collaboration with these pension funds.

 

In addition, I was invited earlier this year by the UK government to co-author with Prof. Irene Tracey, an independent review of the UK’s university spin-out ecosystem. Our review and set of recommendations were published last week. It was an honour to participate in the preparation of this report.  I share my learnings in a blog post below. 

 

Finally, in this newsletter, we are delighted to share with you our 2023 Impact and ESG report.  I would like to congratulate Michelle Lamprecht on the leadership she has shown this year, hosting a recent Mansion House ESG event and joining the Steering Committee for the ESG_VC program. 

 

Andrew Williamson

NEW INVESTMENTS

T Thera

CIC announced its investment in T-Therapeutics, having co-led the £48 million Series A funding alongside leading European and US life science investors Sofinnova Partners, F-Prime Capital and Digitalis Ventures.  The company is based on the pioneering research into T-cell receptor (TCR) therapies that its founder, Professor Allan Bradley, carried out at both the University of Cambridge and the Wellcome Sanger Institute. The investment will be used to further the discovery and development of novel T cell receptor (TCR) therapeutics for cancer treatment, as well as autoimmune and inflammatory disorders.

CIC: A DECADE OF INNOVATION

screen 3

This month we are celebrating our 10th anniversary. To mark the occasion we have created a short animation of some of the key milestones.

BLOG: REVIEW OF THE UK'S SPIN-OUT ECOSYSTEM

spin out doc

What l learnt from co-authoring the first Independent Review of the UK’s University Spin-out Ecosystem

By Andrew Williamson

2023 IMPACT AND ESG REPORT

ESG report 2

We are delighted to share our 2023 Impact and ESG Report, highlighting how we are performing against our objectives, and our progress over the last three years.   

The most attractive companies are those with a sustainable long term business model with the potential to benefit society. Our work with partners, co-investors and the wider industry is helping to instil good ethics, values, and practice from an early stage. 

CIC News 

FT square
TC
FT square
forbes

Jeremy Hunt to offer UK workers 'pot for life’ in sweeping pension reforms

5 investors on the pros and cons of open source ai business models

Cambridge aims t0 double its number of unicorns by 2035

The need for speed - is quantum computing a good space for start-ups?

PORTFOLIO NEWS

imagen final
PM 3
riverlane chip
secondmind

Thomson Reuters signs definitive agreement to acquire Imagen

More animal magic as Zoetis acquires PetMedix

Riverlane announces world's first dedicated Quantum Decoder chip

 

Secondmind expands strategic partnership with Mazda to accelerate vehicle design and development through advanced AI

EVENT WRAP-UP

ESG_VC 2
IC2
lifestar3

In September, CIC co-hosted ESG_VC: The Road Ahead at Mansion House on behalf of ESG_VC. The event brought together leading investors, ESG specialists, LPs and advisers to consider the rapidly evolving landscape of ESG in the venture capital industry.

In October, more than 400 industry, civic and academic leaders came together at The Innovate Cambridge Summit to ensure that Cambridge remains the most intensive science and technological cluster in the world and continues to drive innovation that is central to both the wider UK growth agenda, and local, national, and global prosperity.

In November, CIC hosted the Women-Led Business of the Year award, which recognises the achievements and contributions of women leaders that have shown superior leadership, vision and inspiration, and transformational outcomes for their business and sector. Congratulations to the winner Renee Aguiar-Lucander, CEO of Calliditas Therapeutics.

TEAM 

We are pleased to welcome three new members to the CIC team.

Rupert Baines 

Rupert is an Entrepreneur in Residence. As a seasoned start-up entrepreneur and CEO, he has had leadership roles, founded a number of technology companies and been involved in three successful exits. 

Rupert baines

Matt Maynard 

Matt joined the CIC team as our Events Manager. With 11 years of experience in events and project management, he previously worked as an Events & Marketing Coordinator at Anglia Ruskin University (ARU).

MM4

Stefan Galander

Stefan is an Operations Analyst. He joined CIC from Sana Capital, where he helped to source deals and raise a first-time venture capital fund. 

Stefan Galander
LinkedIn
Twitter

Cambridge Innovation Capital, 22 Station Road, Cambridge, CB1 2JD

Unsubscribe